PATIENT-CENTERED HEALTH CARE VIA PATIENT-GENERATED HEALTH DATA

whitePaper | January 18, 2023

The lifetime success of a pharmaceutical product is determined within the first few months following a product launch. Two-thirds of all product launches underperform and the majority of launches fail due to lack.

whitePaper | April 7, 2022

The United States defines a rare disease as a condition affecting fewer than 200,000 people in the country or one in which “there is no reasonable expectation” of recovering research and development costs.1 Examples of rare diseases include genetically-linked cancers, cystic fibrosis, and debilitating pediatric conditions like Gaucher disease and spinal muscular atrophy

whitePaper | January 1, 2020

With over 2,800 campaigns each year delivered through a team of 300+ digital, data, and technology specialists, Deck 7 is a first resource for B2B demand generation services for marketers worldwide. Clients leverage Deck 7’s multichannel content marketing services and Media 7’s network of 30+ online publications for content syndication to engage over 95 million buyers across 16 industries and 120+ countries.

whitePaper | February 11, 2021

Welcome to Pharmaprojects’ 2021 review of trends in pharmaceutical R&D. For almost 30 years now, I’ve been taking an annual look at the evolution of pharma R&D, and in this article I’ll examine the state of play at the start of 2021.

whitePaper | June 5, 2022

Although our growing scientific understanding and improvements made in medical technology lead to significant advances in human health and wellbeing, many therapy strategies remain insufficient,

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.